Halozyme Therapeutics Inc. (RV7)
FSX
Closed
Aug 25, 2026
Day's Range
92.8452 wk Range
52.50Overview - RV7 - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
10.64B
P/E (Trailing)
‪31.64‬
P/E (Forward)
‪35.26‬
PEG Ratio
‪0.71‬
Price / Sales (TTM)
‪6.30‬
Price / Book
‪84.83‬
EV / EBITDA
‪11.83‬
Profitability
Gross Margin
‪83.54%‬
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
118.61M
Float
112.16M
Held by Insiders
‪1.10%‬
Held by Institutions
‪112.34%‬
Price stats
Beta
‪0.84‬
50-Day Avg
‪72.05‬
200-Day Avg
‪62.06‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - RV7 - Halozyme Therapeutics Inc.
Peers - RV7 - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- RV7FSXHalozyme Therapeutics Inc.10.43BMarket Cap+33.40%52-week change31.83P/E (Trailing)‪24.85%‬Profit Margin
- ANLFSXAnalog Devices, Inc.152.94BMarket Cap+29.62%52-week change44.47P/E (Trailing)‪29.78%‬Profit Margin
- 1AEFSXargenx SE56.27BMarket Cap+30.57%52-week change39.07P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt54.72BMarket Cap+33.14%52-week change39.13P/E (Trailing)‪32.26%‬Profit Margin
- 0QFFSXModerna, Inc.47.69BMarket Cap+84.54%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 42ZFSXRevolution Medicines Inc.37.93BMarket Cap+83.17%52-week change-30.35P/E (Trailing)‪0.00%‬Profit Margin
- 49BAFSXBeOne Medicines, Ltd. American Depositary Receipt35.29BMarket Cap+16.03%52-week change65.41P/E (Trailing)‪10.69%‬Profit Margin
Profile Summary - RV7 - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
